282 results about "Enterobacterales" patented technology

The invention provides a Lactobacillus paracasei, which has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.32951. The Lactobacillus paracasei has a preservation number of CGMCC No.32951. The Lactobacillus paracasei has a preservation number of CGMCC No.32951. The lactobacillus paracasei ID001 provided by the invention has an inhibition effect on enteropathogenic bacteria such as salmonella, escherichia coli, staphylococcus aureus and the like. The probiotic preparation is obtained through fermentation and the dendrobium officinale extract, and the probiotic preparation has the immunoregulation effect through performance verification and screening.

The invention provides an antibacterial peptide cAMP048 sourced from microorganisms in a deep sea environment and application of the antibacterial peptide cAMP048, and belongs to the technical field of peptide inhibitors. The antibacterial peptide cAMP048 has an amino acid sequence as shown in SEQ ID NO: 1 (Sequence Identity Number 1). The antibacterial peptide can inhibit the growth of acinetobacter baumannii at 64 mu M, inhibit the growth of multi-drug-resistant acinetobacter baumannii and multi-drug-resistant enterococcus faecium at 128 mu M and inhibit the growth of escherichia coli, staphylococcus aureus and multi-drug-resistant klebsiella pneumoniae at 256 mu M. The antibacterial peptide can be used for preparing products with antibacterial and / or bactericidal performance, and can be applied to preparation of antibacterial and / or bactericidal products. Such as food, skin care products or medical supplies.

The invention discloses construction and application of an escherichia coli L-tryptophan biosensor, and belongs to the technical field of bioengineering. The L-tryptophan biosensor provided by the invention comprises a mutated leader peptide fragment tnaC-tnaA, a promoter of the mutated leader peptide fragment tnaC-tnaA, a green fluorescent protein coding gene eGFP and a pTrc99a plasmid skeleton, a recombinant strain containing the L-tryptophan biosensor is cultured, the expression of green fluorescent protein in a culture solution is gradually enhanced along with the increase of the concentration of the L-tryptophan, and the fluorescence value of a unit cell shows better correlation when the concentration of the L-tryptophan is 0-1.5 g / L; therefore, when the biosensor is used for detecting the L-tryptophan in the fermentation liquor, the biosensor has the characteristics of simplicity in operation, sensitive response and high threshold value.

The invention discloses a quaternized chitosan benzisothiazolinone derivative as well as a preparation method and application of the quaternized chitosan benzisothiazolinone derivative in efficient antibacterial performance. The derivative has a structure as shown in a formula 1. The preparation method comprises the following steps: reacting chitosan with glycidyl trimethyl ammonium chloride at 60-100 DEG C for 6-48 hours to obtain a product 1, namely hydroxypropyl trimethyl ammonium chloride chitosan (HACC); the preparation method comprises the following steps: reacting 1, 2-benzisothiazolin-3-one with sodium chloroacetate at the temperature of 110-140 DEG C for 12-36 hours to obtain a product 2: 2-(3-carbonyl benzo [d] isothiazole-2-(3H)-yl) acetic acid (BITCOOH); and reacting the product 1 with the product 2 under a neutral condition for 12-48 hours to obtain the quaternized chitosan benzisothiazolinone derivative (HACCBIT). The derivative has a broad-spectrum antibacterial property, and has a killing effect on a plurality of bacteria, such as staphylococcus aureus, escherichia coli, salmonella salmonella salmonella, lactobacillus paracasei, lysinibacillus sphaericus, acinetobacter lwoffii and the like, and the derivative can be used for killing a plurality of bacteria, such as the staphylococcus aureus, the escherichia coli, the salmonella salmonella salmonella, the lactobacillus paracasei, the lysinibacillus sphaericus, the acinetobacter lwoffii and the like.

The invention discloses a bacillus strain H7 and an application thereof. The invention provides bacillus velezensis H7 or a progeny of the bacillus velezensis H7, and the preservation number of the bacillus velezensis H7 in the China Center for Type Culture Collection (CCTCC) is CCTCC NO: M 2025630. The bacillus velezensis H7 disclosed by the invention has a very good antibacterial effect on various common clinical pathogenic bacteria (including klebsiella pneumoniae, escherichia coli, candida albicans, enterobacter cloacae complex, acinetobacter baumannii and the like), and particularly shows a very high inhibition rate on some drug-resistant clinical pathogenic bacteria; therefore, the compound has important application value in development of drug and non-drug antibacterial products (such as medical antibacterial materials and the like), a new choice can be provided for drug and non-drug prevention and control of clinical pathogenic bacterium infection, and particularly, the compound has a supplementary effect in the aspects of reducing drug-resistant bacterium propagation risk and reducing drug dependence.

The invention relates to a method for increasing the yield of L-malic acid produced by fermentation by adding ethylene glycol, which comprises the following steps: constructing genetic engineering escherichia coli, and introducing ethylene glycol metabolism genes (overexpression) including glycerol dehydrogenase, lactaldehyde reductase, lactaldehyde dehydrogenase and the like; and overexpression of other genes involving malic acid production, such as malic acid synthase, phosphoenolpyruvate carboxylase and malic acid export protein. The gene engineering strain is an E.coli BW25113 strain of which ldhA, pta, poxB, adhE, pflB, mgsA, frdA, maeA, maeB, yqhD, ycdW and iclR genes are substantially inactivated, and the deleted genes are beneficial to reducing the generation of metabolic byproducts and increasing the accumulation of malic acid. The genetic engineering strain is subjected to fermentation culture by taking glucose and ethylene glycol as carbon sources, and L-malic acid is separated from a culture after culture is finished.

The present invention discloses a broad-spectrum antibacterial peptide, and the amino acid sequence of the antibacterial peptide is GECEGNNRPVKKPQPRKKLPRFKKC-NH2. Based on melittin, the present invention designs antibacterial peptides by predicting based on a deep learning model, and obtains antibacterial peptides with broad-spectrum bacteriostasis, thermal stability and low hemolytic property, which have good inhibitory effects on skin pathogenic bacteria such as Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans and Propionibacterium acnes. Peptides predicted as AMP amino acid sequences by the deep learning model antibacterial peptide prediction tool amPEPpy are selected for screening, and by using a biosynthesis technique, they are expressed, extracted and purified in Escherichia coli, reducing the workload and screening period of screening, and increasing the probability of screening out broad-spectrum and thermally stable biosynthetic antibacterial peptides.

The invention discloses a saline-alkaline tolerant compound microbial agent and application thereof, and particularly relates to the technical field of microbial soil treatment. The microbial agent comprises Klebsiella, Enterobacter hormaechei and humic acid, the ratio of the components is as follows: Klebsiella: Enterobacter hormaechei: humic acid = 1: (0.5-2): (1-3), and both Klebsiella and Enterobacter hormaechei are obtained by fermentation culture. According to the present invention, the specific pH gradient is adopted for the Klebsiella and the Enterobacter hormaechei, and the segmented fermentation process combining the specific pH gradient with the corresponding gradually-increased sodium chloride concentration is adopted, such that the strain is effectively subjected to the directional domestication so as to maintain the activity and the function in the high-salt and high-alkali extreme environment.

The invention discloses a urinary system infection pathogen and drug resistance gene detection system and a kit. The detection system comprises forward and reverse primers which are respectively used for detecting escherichia coli, staphylococcus aureus, acinetobacter baumannii, klebsiella pneumoniae, enterococcus faecium, candida glabrata, proteus mirabilis, enterococcus faecalis, candida tropicalis, enterobacter cloacae, candida albicans, pseudomonas aeruginosa and streptococcus agalactiae; the forward primer and the reverse primer are respectively used for detecting the blaCTX-M gene of the extended spectrum beta-lactamase, the forward primer and the reverse primer are used for detecting the blaSHV gene of the extended spectrum beta-lactamase, and the forward primer and the reverse primer are used for detecting the blaTEM gene of the extended spectrum beta-lactamase. According to the forward and reverse primers for detecting the blaNDM gene of the extended-spectrum beta-lactamase, a detection sample is urine. According to the invention, common gram-negative bacteria, gram-positive bacteria and fungi can be detected at the same time, and the problem of missed detection of mixed infection in traditional culture is solved.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mh-GC21 as well as a precursor and application thereof. The amino acid sequence of the antibacterial peptide Mh-GC21 provided by the invention is as shown in SEQ ID NO.1, and two cysteines are oxidized to form a pair of intermolecular disulfide bonds; the C tail end of the antibacterial peptide Mh-GC21 is subjected to amidation modification. The antibacterial peptide Mh-GC21 provided by the invention is from microhyla microcarpa, has broad-spectrum antibacterial activity, has relatively good antibacterial and bactericidal effects on standard strains of acinetobacter baumannii, escherichia coli and staphylococcus aureus and clinically sourced drug-resistant strains, and can be used for targeted destruction of cell membranes of bacteria, removal of biological membranes and inhibition of formation of the biological membranes. Moreover, the antibacterial peptide Mh-GC21 has the advantages of good stability, no hemolytic activity and cytotoxicity, and difficulty in inducing strains to generate drug resistance.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an LL-37 derived antibacterial peptide and application thereof. According to the invention, 17-29aa of the LL-37 antibacterial peptide is used as a core fragment and is connected with an amino acid sequence shown as SEQ ID NO: 1 or SEQ ID NO: 2 through an amido bond, the antibacterial activity of the obtained antibacterial peptide is obviously higher than that of the LL-37 antibacterial peptide, and the antibacterial peptide shows an obvious bactericidal effect on clinical drug-resistant bacteria such as acinetobacter baumannii, pseudomonas aeruginosa, escherichia coli, staphylococcus aureus, klebsiella pneumoniae and the like; meanwhile, the cytotoxicity and hemolytic activity are weak, drug resistance is not prone to being generated, bacteria can be rapidly killed in vivo through multiple mechanisms, no obvious cytotoxicity exists, the bacterium load in tissue is remarkably reduced, and the lifetime of a bacterium-infected mouse is prolonged.

The invention provides a method for synthesizing D-psicose through fermentation of escherichia coli by using D-glucose and D-xylose. The method comprises the following steps: by taking escherichia coli as a host cell, over-expressing a galactose permease gene galP, a glucokinase gene glk, a 6-phosphate glucose isomerase gene pgi, a D-psicose-6-phosphate epimerase gene alsE with an SUMO tag and a D-psicose-6-phosphate phosphatase gene a6PP, and constructing a path for synthesizing D-psicose by taking D-glucose and D-xylose as substrates; the synthetic route of D-psicose is optimized by knocking out a D-glucose phosphorylation transport pathway gene ptsG, knocking out D-fructose-6-phosphokinase genes pfkA and pfkB, silencing a glucose-6-phosphate dehydrogenase gene zwf, overexpressing glutamate transhydrogenase genes gdh1 and gdh2, knocking out a UDP-glucose-4-epimerase gene galE and knocking out a transport protein key gene fryA in D-psicose; and finally, the optimal proportion of mixed sugar fermentation is explored, so that efficient synthesis of D-psicose from escherichia coli through mixed sugar fermentation of D-glucose and D-xylose is realized.

The invention discloses an application of NSC348884 in preparation of an antibacterial drug, the bacteria of the NSC348884 are gram-negative bacteria or drug-resistant gram-negative bacteria, and the gram-negative bacteria are acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa or klebsiella pneumoniae; based on an antibacterial drug high-throughput screening technology, it is found from 1280 small molecule compounds that the benzimidazole compound NSC348884 has direct bacteriostasis and sterilization effects on gram-negative bacteria and drug-resistant gram-negative bacteria, and no drug resistance is generated after the benzimidazole compound NSC348884 is continuously applied for 14 days. Further research shows that NSC348884 can interfere with lipid synthesis of gram-negative bacterium cell membranes, inhibit formation of biological membranes and induce lipid metabolism disorder, so that bacteriostatic and bactericidal effects are achieved. In addition, the NSC348884 can also enhance the sensitivity of the drug-resistant bacteria to the imipenem and the polymyxin B.

The invention provides a fluorenyl alcohol derivative which can be used as an antibiotic adjuvant with a broad-spectrum synergistic effect. According to the compound, bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are taken as targets, and a series of fluorenyl alcohol derivatives targeting the bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are obtained through screening. The preferable compound WTU-15 can improve the antibacterial activity of antibiotics such as polymyxin, cefepime, tetracycline and the like on negative bacteria such as sensitive and drug-resistant escherichia coli, salmonella, klebsiella pneumoniae, acinetobacter baumannii and the like, and can also improve the in-vivo treatment effect of cefepime on mice infected by the drug-resistant acinetobacter baumannii. And the visceral organs of the mice survived after administration have fewer bacteria, and the mice are better after being healed. Normal physiological and visceral organ functions of the mouse are not affected by single and continuous administration of the WTU-15.

The invention discloses an antibacterial composition which comprises 5-8 wt% of sodium lauroyl sarcosinate, 5-8 wt% of cocamidopropyl betaine and 2-4 wt% of sodium laureth sulfate, the pH value is 4-5.5, through reasonable combination and compatibility of different surfactants, the antibacterial composition has an obvious antibacterial synergistic effect, the antibacterial rates of candida albicans, staphylococcus aureus and escherichia coli are all larger than 90%, and the antibacterial effect is good. The compound can be used for preparing various washing and nursing materials such as laundry detergents, hand sanitizers, bath foam and private part care solutions.

The invention discloses a method for producing L-arginine through escherichia coli fermentation. The escherichia coli has the characteristics of high L-arginine yield and low heteroacid content. In the fermentation process, fed-batch sugar and sodium glutamate are adopted according to the thallus concentration OD600 and the fermentation period; the concentration of glutamic acid is controlled by feeding sodium glutamate or glutamic acid precursor sodium succinate and sodium citrate, the arginine acid production and sugar acid conversion rate is increased, the content of heteroacid is reduced, the final acid production can reach 13.9% at most, the sugar acid ratio is 57.2%, and the heteroacid content is not higher than 0.3%. The process solves the control difficulty in the industrial process of arginine, and has great commercial value.

The invention relates to the technical field of PA resin, and particularly discloses glass fiber modified antibacterial PA resin suitable for children products and a preparation method of the antibacterial PA resin. The invention discloses glass fiber modified antibacterial PA resin suitable for children products. The glass fiber modified antibacterial PA resin comprises PA resin, glass fibers, talcum powder, nano calcium carbonate, a composite antibacterial agent, a compatilizer, an antioxidant and calcium stearate, the composite antibacterial agent comprises chitosan, an antibacterial peptide microcapsule and a porous silver-zinc-loaded antibacterial agent; the antibacterial peptide microcapsules are sodium alginate embedded antibacterial peptides. The antibacterial PA resin obtained in the invention has the highest bacteriostasis rates of 99.97%, 99.74% and 99.95% for staphylococcus aureus, escherichia coli and candida albicans respectively, the antibacterial property of the PA resin is improved, the compressive strength and notch impact strength are 170.6 MPa and 17.3 kJ / m < 2 > respectively, and high mechanical strength is maintained on the basis of high antibacterial property.

The invention discloses a lactobacillus plantarum YM-7, the preservation number of the lactobacillus plantarum YM-7 in Guangdong Microbial Culture Collection Center is GDMCC No: 65465, and the lactobacillus plantarum YM-7 obtained from fermented food is high in safety, has an inhibition effect on staphylococcus aureus, escherichia coli and candida albicans, and can be used for preparing a food additive. The strain TN-7 has the effect of removing DPPH, hydroxyl free radicals and superoxide anion free radicals, so that the strain TN-7 can be used as a food additive, and a new way is provided for development of antioxidant and antibacterial food additives.

The invention relates to a cow's milk endogenous antibacterial peptide and application thereof, the cow's milk endogenous antibacterial peptide is an antibacterial peptide compound PKTKVIPYVRYL from endogenous enzyme hydrolyzed bovine casein, and the amino acid sequence of the antibacterial peptide compound is Pro-Lys-Thr-Lys-Val-Ile-Pro-Tyr-Val-Arg-Tyr-Leu. The compound has wide inhibitory activity on gram-positive bacteria and gram-negative bacteria, including porphyromonas gingivalis, escherichia coli, staphylococcus aureus and the like, respectively. The antibacterial peptide can be used as a health care product and / or a medical instrument or a medicine for preventing and / or reducing infectious diseases, a food bacteriostatic agent, novel functional food, pet food, an animal feed additive and daily chemicals and has a good application prospect.

The invention discloses a larimichthys crocea IL-22 recombinant protein which is a larimichthys crocea IL-22 mature peptide sequence, and the amino acid sequence of the larimichthys crocea IL-22 recombinant protein is as shown in SEQ ID NO. 2. The recombinant protein is obtained by amplifying and coding gene segments of amino acids from 31st to 190th positions of large yellow croaker IL-22 mature peptide through PCR (Polymerase Chain Reaction), and transforming escherichia coli for heterologous expression. The larimichthys crocea IL-22 recombinant protein can activate a transcription factor STAT3 in a larimichthys crocea head kidney cell line (LYCK) and also can induce expression of inflammatory factors (IL-1beta, IL-6 and IL-8) in immune organs of larimichthys crocea, so that the larimichthys crocea IL-22 recombinant protein has an obvious immunoregulation effect and shows a good application prospect in research and development of aquatic immunomodulators.

The invention belongs to the technical field of microorganisms, and particularly discloses lactobacillus plantarum CX1-3-2 capable of producing gamma-aminobutyric acid and improving sleep and application of the lactobacillus plantarum CX1-3-2. The preservation number of the lactobacillus plantarum CX1-3-2 strain is CGMCC (China General Microbiological Culture Collection Center) No. 34340. The lactobacillus plantarum CX1-3-2 can achieve the effect of improving sleep by improving the levels of GABA and 5-HT in brain tissues and reducing the levels of glutamic acid Glu, dopamine DA and noradrenaline NE; the scavenging rate of DPPH free radicals of the strain reaches 96.4%, the scavenging rate of ABTS free radicals of the strain reaches 78.3%, and the strain has an excellent anti-oxidation effect; the diameters of inhibition zones of the strain on staphylococcus aureus, bacillus cereus, escherichia coli and pseudomonas fluorescens are all larger than 17 mm, and the strain has an excellent antibacterial effect.

The invention discloses a tannic acid-silver palladium (TA-Ag / Pd) nano material and a preparation method and application thereof, and belongs to the technical field of biological materials.The method comprises the steps that Na2PdCl4 is added into water containing HCl, and a palladium solution is obtained; the palladium solution and the silver nitrate solution are added into the tannic acid solution for vortex mixing, and a mixed solution is obtained; and carrying out constant-temperature treatment on the mixed solution, washing, centrifuging and drying to obtain the TA-Ag / Pd nano material. The preparation method provided by the invention is mild in reaction condition, simple and convenient in preparation process, short in time and high in efficiency, and the prepared TA-Ag / Pd nano-material shows a remarkable antibacterial effect, can effectively inhibit growth of bacteria such as escherichia coli and staphylococcus aureus, is suitable for the fields of medical instruments, food packaging, environmental protection and the like, and has wide application prospects. The method has remarkable application advantages and wide market potential.

The invention relates to the technical field of microbiological detection, and particularly discloses a primer probe combination for detecting six food-borne pathogens and application of the primer probe combination. The detection primer probe combination for the six food-borne pathogens comprises six pairs of specific primer pairs and six probes, the nucleotide sequences of the specific primer pairs are respectively shown as SEQ ID NO.1, SEQ ID NO.4, SEQ ID NO.8, SEQ ID NO.1, SEQ ID NO.13, SEQ ID NO.16, SEQ ID NO.19, SEQ ID NO.22, SEQ ID NO.26, SEQ ID NO.29, SEQ ID NO.32 and SEQ ID NO.35, and the nucleotide sequences of the probes are respectively shown as SEQ ID NO.37-SEQ ID NO.42; the six food-borne pathogens comprise listeria monocytogenes, salmonella, vibrio parahaemolyticus, norovirus, escherichia coli O157: H7 and staphylococcus aureus. According to the present invention, the pathogens of six common food-borne diseases can be detected, the detection method has characteristics of high specificity and high sensitivity, and the pathogens do not interfere with each other and do not inhibit each other during the detection so as to achieve good stability.

According to the probiotic composition and the application of the probiotic composition in preparation of products for preventing and treating vagina inflammation, the probiotic composition composed of lactobacillus gasseri B13.52 and lactobacillus mucus B14.46 screened from vaginal secretion of healthy women can effectively inhibit growth of escherichia coli, gardnerella and prevotella; the secretion of proinflammatory factors in vaginal epithelial cells can be obviously reduced, so that an anti-inflammatory effect is achieved.

The invention provides a red light carbon quantum dot as well as a preparation method and application thereof. The red light carbon quantum dot is prepared from fulvic acid and polyamine as raw materials through a hydrothermal reaction. The fulvic acid is used as a carbon source, the polyamine is used as a nitrogen source, the carbon quantum dots are prepared through a hydrothermal reaction, the obtained carbon quantum dots are small in size, and the particle size is 1-3 nm; the red light emission wavelengths are 680 nm and 720 nm, and the photoluminescence characteristic is irrelevant to the excitation wavelength; the prepared quantum dot has good biocompatibility, the quantum efficiency is greater than or equal to 20%, the prepared quantum dot has good bacteriostatic and antibacterial activity, and the inhibition rate on staphylococcus aureus, pseudomonas aeruginosa, enterobacter cloacae, escherichia coli, klebsiella pneumoniae or methicillin-resistant staphylococcus aureus under the concentration of 2 mu g / mL can reach 99.9%. Wide application prospects are realized in the aspects of antisepsis, anti-inflammation and wound healing promotion.

The present invention relates to the pharmaceutical field, and provides a boric acid β-lactamase inhibitor or a use thereof. The boric acid β-lactamase inhibitor is a compound shown in formula (I), or an optical isomer or a pharmaceutically acceptable salt thereof: formula (I). The ultra-broad-spectrum boric acid β-lactamase inhibitor of the present invention has an inhibition effect on A, B, C, and D enzymes, and carbapenem drug-resistant bacteria such as Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, Acinetobacter baumannii, and Pseudomonas aeruginosa.

The invention relates to the technical field of bioengineering, in particular to a penicillin G acylase mutant, polynucleotide, an expression vector and application. The penicillin G acylase mutant is obtained by carrying out site-directed mutagenesis on a wild type penicillin G acylase gene of parent Escherichia coli, and carrying out site-directed mutagenesis on the wild type penicillin G acylase gene to obtain the penicillin G acylase mutant. Phenylalanine (F) at the 24th site of an alpha chain, proline (P) at the 383rd site of a beta chain, threonine (T) at the 384th site of the beta chain, glutamic acid (G) at the 385th site of the beta chain and serine (S) at the 386th site of the beta chain of the penicillin G acylase are introduced and mutated by a whole plasmid PCR (Polymerase Chain Reaction) technology to obtain mutants. When the penicillin G acylase mutant obtained by the invention is used for catalyzing methyl mandelate and 3-(1-methyl-1H-tetrazole-5-yl) thiomethyl-7-aminocephalosporanic acid to synthesize cefamandole, the synthesis activity is improved, and meanwhile, the side reaction rate is greatly reduced.

The invention belongs to the technical field of bioengineering, and relates to bacillus orientalis and application thereof in bacteriostasis and disease prevention, in particular to bacillus orientalis P2-1 and a microbial agent thereof, and application of the bacillus orientalis P2-1 and the microbial agent in inhibition of pathogenic bacteria in water and prevention of river crab diseases. The bacillus subtilis has a good phagocytosis effect on pathogenic bacteria such as pseudomonas aeruginosa, shewanella alga, citrobacter freundii, klebsiella pneumoniae and enterobacter glycosides, and can be used for remarkably removing the pathogenic bacteria such as the pseudomonas aeruginosa, the shewanella alga, the citrobacter freundii, the klebsiella pneumoniae and the enterobacter glycosides in a water body; the pseudomonas disease of the river crabs is effectively prevented and controlled, and a good effect is achieved on simultaneously preventing black gill disease, hepatopancreas necrosis disease, water shriveled disease, enteritis disease, edema disease and trembling disease in the culture and production of the river crabs.

The invention provides an engineering strain for reducing by-products quinic acid and glutamic acid in the process of biosynthesizing shikimic acid and application of the engineering strain, and belongs to the technical field of bioengineering.According to the engineering strain, an escherichia coli recombinant strain HYY1458 serves as an initial strain, quinic acid dehydrogenase (ydiB) is knocked out, so that the synthetic route of quinic acid is blocked, and the yield of the shikimic acid is increased; glutamate synthetase (gltB) and glutamate dehydrogenase (gdhA) are knocked out to partially hinder a glutamic acid synthesis route, the constructed strain is named as an escherichia coli engineering strain YY1127, the escherichia coli engineering strain YY1127 is used for fermentation culture, the content of quinic acid and glutamic acid is reduced by 85.3%, the purity of biosynthesized shikimic acid is improved, and the yield of the shikimic acid is increased. The subsequent separation and purification difficulty is reduced.

The invention provides a primer group, a kit and a method for simultaneously detecting 11 microorganisms and diagnosing chronic endometritis intrauterine infection. The primer group is used for detecting the existence of 11 chronic endometritis pathogens: chlamydia trachomatis, enterococcus faecalis, escherichia coli, trichomonas vaginalis, klebsiella pneumoniae, mycoplasma hominis, neisseria gonorrhoeae, staphylococcus, streptococcus, reproductive mycoplasma and ureaplasma urealyticum. The primer group is used for performing multiple joint detection on chronic endometritis related pathogens, has high specificity and sensitivity, and is adaptive to an endometrial tissue sample. The invention provides a method for simultaneously detecting 11 microorganisms for diagnosing chronic endometritis intrauterine infection, which comprises the following steps of: collecting an endometrial sample by adopting a disposable sterile endometrial sampler, detecting 11 microorganisms in the endometrial sample by adopting a multiplex PCR (Polymerase Chain Reaction) technology, and accurately detecting the intrauterine microbial infection condition. Meanwhile, more accurate technical support is provided for clinically identifying whether pathogenic bacteria causing chronic endometritis exist or not, and clinical doctors can comprehensively consider medication guidance conveniently.